NASDAQ, AMEX, NYSE Stocks Discuss depo DepoMed Inc. in the Stock Market Forum forums; good buying opportunity?...

ronron · #1 07-10-2007, 06:33 PM

good buying opportunity?

proclivity · #2 07-13-2007, 09:32 PM

Quote:

Originally Posted by ronron

good buying opportunity?

ticker?

I am too lazy to look for it. Seriously....it takes about 2.2 seconds with a broadband connection and i could have figured it out before i finished typing this useless post. Go figure.

Ciao · #3 07-14-2007, 01:42 AM

Quote:

Originally Posted by ronron

good buying opportunity?

I got this one signal yesterday (thursday 12/07) on an Italian forum
it closed at +18.5 (got in/out) after a big drop (-55%+/-) from the day before

I was waiting for someone to open a thread ..

hey Ronron where are all the inforegarding DEPO
+ needed when opening a thread.... ;)

ok I try to help, but as you started you can carry it on...

Ciao · #4 07-14-2007, 01:45 AM

DEPO:Nasdaq
Web Site: http://www.depomedinc.com

Quote:

Depomed, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products based on its proprietary oral drug delivery technologies in the United States. Its primary oral drug delivery system, AcuForm is a polymer-based drug delivery platform that provides targeted drug delivery solutions for various compounds. The company's product line comprises Glumetza for the treatment of Type II diabetes; ProQuin XR for the treatment of uncomplicated urinary tract infections; and Gabapentin GR for the treatment of two pain indications, postherpetic neuralgia and diabetic peripheral neuropathy. In addition, the company is developing other product candidates for the treatment of gastroesophageal reflux disease. The company has collaborations with New River Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Patheon, Inc.; and Biovail Corporation. Depomed was founded in 1995 and is headquartered in Menlo Park, California

Ciao · #5 07-14-2007, 01:57 AM

10 July 2007, 08:36am ET

Quote:

(RTTNews) - Shares of Depomed (DEPO) dropped sharply in pre-market trading on Tuesday, hurt by disappointing results of a late-stage drug trial. The stock fell $1.83 before the opening bell to reach $4.93. This represented a decline of nearly 63%.

Depomed announced that a phase III trial of Gabapentin GR failed to show statistically significant efficacy relative to a placebo. Gabapentin GR is an investigational extended release tablet for the treatment of patients with postherpetic neuralgia, a persistent neuropathic pain condition caused by nerve damage after a shingles, or herpes zoster, viral infection.

Ciao · #6 07-14-2007, 02:04 AM

more info
http://finance.yahoo.com/q?s=depo
http://www.investorim.com/home/index...33&ticker=depo

Ronron from now on it is all yours... ;)